Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial
Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM
Published in Journal of Allergy and Clinical Immunology: In Practice, Vol. 6 (3), pp. 825-831
Methodology
Prospective, single-arm, non-blinded dietary pilot in 10 adults with aspirin-exacerbated respiratory disease (AERD). Participants aimed to cut dietary omega-6 fatty acids to under 4 g/day and raise omega-3 intake to over 3 g/day for two weeks. The primary outcome was urinary leukotriene E4.
Key Findings
Urinary leukotriene E4 fell by 0.17 ng/mg and the prostaglandin D2 metabolite tetranor-PGDM by 0.66 ng/mg creatinine (both P = .02). The SNOT-22 sinus symptom score improved by 15.1 points (P = .01) and asthma control by 0.27 points (P = .03), with no change in lung function.
Conclusions
A high omega-3, low omega-6 diet may be a reasonable adjunct treatment for AERD.
Limitations
Ten participants, no control group, participants knew their diet, two-week duration, and all participants lost some weight, which could affect the results.
Supplements Studied
may be an appropriate adjunct treatment option for patients with AERD
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.